MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cyclacel Pharmaceuticals Company Profile (NASDAQ:CYCC)

Consensus Ratings for Cyclacel Pharmaceuticals (NASDAQ:CYCC) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $60.00 (1,067.32% upside)

Analysts' Ratings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Show:
DateFirmActionRatingPrice TargetActions
10/16/2015HC WainwrightInitiated CoverageBuy$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2014JMP SecuritiesDowngradeOutperform -> Market Perform$108.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/11/2016Q116($0.09)$512.00 million$139.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2016Q4($0.08)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.09)($0.08)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.25)($0.19)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2015Q414($0.26)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314($0.26)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.30)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.26)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2014Q413($0.33)($0.19)$0.09 million$0.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.31)($0.31)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q2 2013($0.10)$0.03 million$0.26 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2013Q1 2013($1.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2012Q312($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/20/2014Sam L BarkerDirectorBuy3,100$3.00$9,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Lloyd SemsDirectorBuy33,333$3.00$99,999.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Paul McbarronCFOBuy12,948$3.03$39,232.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Spiro George RombotisInsiderBuy100,000$3.00$300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
DateHeadline
06/26/16 08:36 AMStrong Sell Calls Recommendations For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0 - Investor Newswire
06/24/16 10:16 AMCyclacel Pharma (CYCC) Enters $4M At Market Issuance Sales Agreement
06/23/16 08:30 PMNew Broker Ratings For Cyclacel Pharmaceuticals, Inc. (CYCC) - FTSE News
06/23/16 08:30 PMCyclacel Pharma (CYCC) Enters $4M At Market Issuance Sales Agreement - StreetInsider.com
06/23/16 03:39 PMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mater -
06/22/16 03:42 PMCyclacel Pharmaceuticals, Inc. (CYCC) Current Analyst Ratings - Fiscal Standard
06/19/16 07:59 AMStrong Buy Calls Count For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 1 - Investor Newswire
06/17/16 03:24 PMEndocyte, Inc. (NASDAQ:ECYT) increased 1.10%: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Freeport ... - KC Register
06/16/16 03:32 PMCyclacel Pharma (CYCC) Regains Nasdaq Listing Compliance - StreetInsider.com
06/08/16 10:29 AMStocks inside Analysts Spotlight: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) , Skyline Medical Inc. (NASDAQ ... - Street Updates
06/07/16 03:36 PMAnalyst Overview: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) - News Oracle
06/07/16 03:36 PMCyclacel Pharmaceuticals (NASDAQ:CYCC) & Kite Pharma Inc (NASDAQ:KITE) Healthcare Stocks on the Run - Wall Street 24
06/07/16 11:22 AMActive Stocks in Pre-Market: Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC), Amazon.com, Inc.(NASDAQ:AMZN) - iStreetWire
06/06/16 03:21 PMCyclacel Pharmaceuticals, (NASDAQ:CYCC) Went Down -3.89%: Cynapsus Therapeutics (NASDAQ:CYNA), Twenty ... - KC Register
06/06/16 03:21 PMCyclacel Pharmaceuticals Inc (CYCC) Stock Shoots up on Phase 1 DNA Damage Response Program Data - Bidness ETC
06/06/16 03:13 PMCyclacel Pharma (CYCC) Stock Skyrockets 50% on Positive Phase 1 Data -
06/03/16 12:04 PMCYCLACEL PHARMACEUTICALS, INC. Financials -
06/01/16 09:42 PMBroker Watchlist: Cyclacel Pharmaceuticals, Inc. (CYCC) - Share Trading News - Broker Watchlist: Cyclacel Pharmaceuticals, Inc. (CYCC)Share Trading NewsThey now have a USD 9 price target on the stock. The share price of Cyclacel Pharmaceuticals, Inc. (CYCC) was unchanged +0.00% during the last trading session, with a day high of 0.00. 0 shares were traded on Cyclacel Pharmaceuticals, Inc.'s last ...
06/01/16 12:32 PMCyclacel Pharmaceuticals, Inc. :CYCC-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/31/16 03:36 PMStrong Sell Calls Count For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0 - Investor Newswire - Strong Sell Calls Count For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0Investor NewswireCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has a total of 1 Strong Buy calls and 0 Strong Sell advises as of 2016-05-30. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is ...and more »
05/31/16 06:03 AMSplits Calendar: Cyclacel Pharma splits before market open today (1:12 ratio) -
05/27/16 04:07 PMCyclacel Announces Reverse Stock Split - [at noodls] - May 27, 2016 BERKELEY HEIGHTS, N.J., May 27, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ('Cyclacel' or the 'Company'), a biopharmaceutical company developing oral ...
05/27/16 04:06 PMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to -
05/27/16 11:41 AMHold Calls Count For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0 - RealistInvestor.com - Hold Calls Count For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0RealistInvestor.comBuy calls count on Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)'s stock stands at 0 while Sell recommendations is 0. Hold recommendation is 0. Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has a total of 1 Strong Buy recommendations and 0 Strong ...and more »
05/25/16 01:12 PMTrader's Watch List: Cyclacel Pharmaceuticals, (NASDAQ:CYCC), Concord Medical Services (NYSE:CCM), M/I Homes ... - KC Register - Trader's Watch List: Cyclacel Pharmaceuticals, (NASDAQ:CYCC), Concord Medical Services (NYSE:CCM), M/I Homes ...KC RegisterCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) announced the publication of an abstract selected for an oral presentation on Phase 1 data of an orally administered, combination regimen of seliciclib and sapacitabine in 67 patients with advanced solid ...What's in Cyclacel Pharmaceuticals Inc After Forming Multiple Bottom Pattern?Franklin Independentall 2 news articles »
05/21/16 12:59 PMRevenue Update on Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC) - Trade Calls - Revenue Update on Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC)Trade CallsCyclacel Pharmaceuticals Inc(NASDAQ:CYCC) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 11, 2016. Earnings per share were $-0.09. Cyclacel Pharmaceuticals Inc (CYCC) made into the ...
05/20/16 01:24 PMCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) One-Year Price Projection At $5 - Investor Newswire - Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) One-Year Price Projection At $5Investor NewswireSell-side analysts are certain on the prospect of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) stock. As of 2016-05-19, the stock ABR stands at 1. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in ...and more »
05/19/16 06:22 AMCyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting - [at noodls] - May 19, 2016 BERKELEY HEIGHTS, N.J., May 19, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the publication of an abstract ...
05/19/16 06:00 AMCyclacel’s Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting - [GlobeNewswire] - BERKELEY HEIGHTS, N.J., May 19, 2016-- Cyclacel Pharmaceuticals, Inc., today announced the publication of an abstract selected for an oral presentation on Phase 1 data of an orally administered, combination ...
05/17/16 01:55 PMAfter Last Week What Do Analysts Think Of Cyclacel Pharmaceuticals, Inc. (CYCC) - Share Trading News - After Last Week What Do Analysts Think Of Cyclacel Pharmaceuticals, Inc. (CYCC)Share Trading NewsThey now have a USD 9 price target on the stock. The share price of Cyclacel Pharmaceuticals, Inc. (CYCC) was up +5.69% during the last trading session, with a day high of 0.37. 83376 shares were traded on Cyclacel Pharmaceuticals, Inc.'s last session.
05/15/16 07:18 AMCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) One-Year Mean Price Target At $5 - Investor Newswire - Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) One-Year Mean Price Target At $5Investor NewswireSell-side analysts are confident on the future outlook of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) stock. As of 2016-05-13, the stock has an ABR of 1 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the basis of ...and more »
05/13/16 03:15 PMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report -
05/12/16 07:52 AMCyclacel Pharma (CYCC) Reports Q1 Loss of $0.09 - StreetInsider.com - Cyclacel Pharma (CYCC) Reports Q1 Loss of $0.09StreetInsider.comCyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($0.09), versus ($0.19) reported last year. Revenue for the quarter came in at $139 million, versus $512 million reported last year. Based on current plans, the Company estimates that it has capital ...and more »
05/12/16 07:52 AMCyclacel Pharmaceuticals Inc (CYCC) Releases Quarterly Earnings Results - Washington News Wire - Washington News WireCyclacel Pharmaceuticals Inc (CYCC) Releases Quarterly Earnings ResultsWashington News WireCyclacel Pharmaceuticals Inc (NASDAQ:CYCC) announced its earnings results on Wednesday. The company reported ($0.09) earnings per share for the quarter, MarketBeat.Com reports. Separately, Zacks Investment Research downgraded shares of ...Cyclacel Pharmaceuticals Inc (CYCC) Announces Earnings ResultsWeb Breaking NewsCyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2016 Results - Earnings Call TranscriptSeeking AlphaCyclacel Pharmaceuticals Reports First Quarter 2016 Financial ResultsGlobeNewswire (press release)Sonoran Weekly Reviewall 5 news articles »
05/11/16 04:07 PMCyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results - [at noodls] - May 11, 2016 BERKELEY HEIGHTS, N.J., May 11, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ('Cyclacel' or the 'Company'), a biopharmaceutical company developing oral ...
05/11/16 06:07 AMQ1 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market Close -
05/05/16 07:21 AMCyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results - GlobeNewswire (press release) - Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial ResultsGlobeNewswire (press release)BERKELEY HEIGHTS, N.J., May 04, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell ...and more »
05/04/16 06:00 AMCyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results - [GlobeNewswire] - BERKELEY HEIGHTS, N.J., May 04, 2016-- Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer ...
05/03/16 07:00 AMBroker Outlook For The Week Ahead: Cyclacel Pharmaceuticals, Inc. (CYCC) - Share Trading News - Broker Outlook For The Week Ahead: Cyclacel Pharmaceuticals, Inc. (CYCC)Share Trading NewsThey now have a USD 9 price target on the stock. The share price of Cyclacel Pharmaceuticals, Inc. (CYCC) was down -7.14% during the last trading session, with a day high of 0.43. 123897 shares were traded on Cyclacel Pharmaceuticals, Inc.'s last ...Morning Watch List: Baxalta (NYSE:BXLT), Supreme Industries (NYSEMKT:STS), Cyclacel Pharmaceuticals, Inc ...KC Registerall 2 news articles »
04/30/16 07:20 AMCyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) Shorted Shares Decreased By 26.88% - B.O.D.Y Confidential - Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) Shorted Shares Decreased By 26.88%B.O.D.Y ConfidentialThe short interest to Cyclacel Pharmaceuticals Incorporated's float is 0.39%. The stock decreased 7.14% or $0.03 on April 29, hitting $0.39. About 123,897 shares traded hands or 10.42% up from the average. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) ...and more »
04/30/16 07:20 AMCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) ABR of 1 - Investor Newswire - Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) ABR of 1Investor NewswireAnalysts have a buy call on Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) stock. As of 2016-04-28, the stock has an ABR of 1. This rating comes on a scale of 1-5, where one makes a strong buy call, and 3 indicates Strong Sell. This ABR computation is ...and more »
04/28/16 07:25 AMBroker Roundup For Cyclacel Pharmaceuticals, Inc. (CYCC) - Share Trading News - Broker Roundup For Cyclacel Pharmaceuticals, Inc. (CYCC)Share Trading NewsThey now have a USD 9 price target on the stock. The share price of Cyclacel Pharmaceuticals, Inc. (CYCC) was up +1.17% during the last trading session, with a day high of 0.45. 95178 shares were traded on Cyclacel Pharmaceuticals, Inc.'s last session.
04/26/16 08:18 AMCyclacel Pharmaceuticals, Inc. (CYCC) Updated Broker Ratings - Risers & Fallers - Cyclacel Pharmaceuticals, Inc. (CYCC) Updated Broker RatingsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Cyclacel Pharmaceuticals, Inc. (CYCC). According to the latest broker reports outstanding on Tuesday 26th of April, 0 analysts have a rating of “strong buy”, 0 ...Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) Shorted Shares Increased 6.39% After Market SellingFranklin Independentall 2 news articles »
04/25/16 07:58 AMCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Reported Comprehensive Income Of $-0.596 - Stocks Daily - Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Reported Comprehensive Income Of $-0.596Stocks DailyFor the period ended 2015-12-31, Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted comprehensive income of $-0.596 millions. The comprehensive income for the three-month ended 2015-12-31 was $-0.596 millions. Cyclacel Pharmaceuticals, Inc.Next Weeks Broker Price Targets For Cyclacel Pharmaceuticals, Inc. (CYCC)Share Trading Newsall 2 news articles »
04/22/16 08:30 AMCyclacel Pharmaceuticals, Inc. (CYCC) Latest Broker Coverage - Risers & Fallers - Cyclacel Pharmaceuticals, Inc. (CYCC) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Cyclacel Pharmaceuticals, Inc. (CYCC). According to the latest broker reports outstanding on Friday 22nd of April, 0 analysts have a rating of “strong buy”, 0 ...
04/21/16 08:25 AMCyclacel Pharmaceuticals Inc (NASDAQ:CYCC)'s CYC065 Induces Cell Death In B-Cell Lymphoma - Journal Transcript - Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)'s CYC065 Induces Cell Death In B-Cell LymphomaJournal TranscriptThe company has already asked its shareholders to approve reverse stock split in order to comply with the listing rules. In case, Cyclacel fails to meet the minimum bid price requirement before June 14, 2016, then it might have to face suspension from ...
04/20/16 08:50 AMPreclinical Data Presented at the AACR 2016 Meeting - BERKELEY HEIGHTS, N.J., April 18, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the presentation of preclinical data demonstrating therapeutic potential of CYC065, ...
04/18/16 08:26 AMCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Reported Comprehensive Income Of $-0.596 For Period Ended 2015 ... - Stocks Daily - Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Reported Comprehensive Income Of $-0.596 For Period Ended 2015 ...Stocks DailyFor the annual period ended 2015–1-2-31, Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted comprehensive income of $-0.596 millions. On quarterly basis, comprehensive income was $-0.596 millions was the three-month period ended 2015–1-2-31.
04/18/16 08:00 AMCyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors - [GlobeNewswire] - BERKELEY HEIGHTS, N.J., April 18, 2016-- Cyclacel Pharmaceuticals, Inc., today announced the presentation of preclinical data demonstrating therapeutic potential of CYC065, the Company’ s second-generation, ...
03/01/16 02:58 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Cyclacel Pharmaceuticals, Inc. - [Business Wire] - Levi & Korsinsky announces it has commenced an investigation of Cyclacel Pharmaceuticals, Inc. concerning possible breaches of fiduciary duty by the board of directors of the company.
About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the immune system to treat cancer and other serious illnesses. The Company develops proprietary techniques of antibody engineering to develop antibody-based products for the applications in immunology, oncology, and infectious diseases. Xcyte Therapies is currently conducting Phase I/II clinical trials in hormone-refractory prostate cancer, multiple myeloma and chronic lymphocytic leukemia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYCC
  • CUSIP:
Key Metrics:
  • Previous Close: $5.14
  • 50 Day Moving Average: $4.97
  • 200 Day Moving Average: $4.98
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $15.45M
  • Current Quarter EPS Consensus Estimate: $-0.49 EPS
Additional Links:
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha